Standard Operating Margin from 2010 to 2024
| LAB Stock | USD 1.60 0.02 1.23% |
Check Standard Biotools financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Standard Biotools' main balance sheet or income statement drivers, such as Depreciation And Amortization of 10.8 M, Interest Expense of 4.5 M or Total Revenue of 85.3 M, as well as many indicators such as Price To Sales Ratio of 1.56, Dividend Yield of 0.0 or PTB Ratio of 2.08. Standard financial statements analysis is a perfect complement when working with Standard Biotools Valuation or Volatility modules.
Standard | Operating Margin |
Latest Standard Biotools' Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Standard Biotools over the last few years. It is Standard Biotools' Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Standard Biotools' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (0.29) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Standard Operating Margin Regression Statistics
| Arithmetic Mean | (0.54) | |
| Coefficient Of Variation | (42.16) | |
| Mean Deviation | 0.16 | |
| Median | (0.45) | |
| Standard Deviation | 0.23 | |
| Sample Variance | 0.05 | |
| Range | 0.9342 | |
| R-Value | (0.57) | |
| Mean Square Error | 0.04 | |
| R-Squared | 0.33 | |
| Significance | 0.03 | |
| Slope | (0.03) | |
| Total Sum of Squares | 0.73 |
Standard Operating Margin History
About Standard Biotools Financial Statements
Standard Biotools stakeholders use historical fundamental indicators, such as Standard Biotools' Operating Margin, to determine how well the company is positioned to perform in the future. Although Standard Biotools investors may analyze each financial statement separately, they are all interrelated. For example, changes in Standard Biotools' assets and liabilities are reflected in the revenues and expenses on Standard Biotools' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Standard Biotools. Please read more on our technical analysis and fundamental analysis pages.
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California. Standard Biotools operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 615 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Standard Biotools offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Standard Biotools' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Standard Biotools Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Standard Biotools Stock:Check out the analysis of Standard Biotools Correlation against competitors. For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Standard Biotools. If investors know Standard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Standard Biotools listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.69) | Revenue Per Share 0.558 | Quarterly Revenue Growth (0.14) | Return On Assets (0.15) | Return On Equity (0.37) |
The market value of Standard Biotools is measured differently than its book value, which is the value of Standard that is recorded on the company's balance sheet. Investors also form their own opinion of Standard Biotools' value that differs from its market value or its book value, called intrinsic value, which is Standard Biotools' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Standard Biotools' market value can be influenced by many factors that don't directly affect Standard Biotools' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Standard Biotools' value and its price as these two are different measures arrived at by different means. Investors typically determine if Standard Biotools is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Standard Biotools' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.